Inhibition of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin.

M. Sinensky,J. Logel

DOI: https://doi.org/10.1016/s0021-9258(18)32090-8

IF: 5.485

1983-07-25

Journal of Biological Chemistry

Abstract:

What problem does this paper attempt to address?

Clinical outcomes of sacral neuromodulation in non-neurogenic, non-obstructive dysuria: A 5-year retrospective, multicentre study in China

Ling-Feng Meng,Wei Zhang,Jian-Ye Wang,Yao-Guang Zhang,Peng Zhang,Li-Min Liao,Jian-Wei Lv,Qing Ling,Zhong-Qing Wei,Tie Zhong,Zhi-Hui Xu,Wei Wen,Jia-Yi Li,De-Yi Luo

DOI: https://doi.org/10.12998/wjcc.v8.i12.2494

2020-06-26

World Journal of Clinical Cases

Abstract:BACKGROUND: Management of non-neurogenic, non-obstructive dysuria represents one of the most challenging dilemmas in urological practice. The main clinical symptom is the increase in residual urine. Voiding dysfunction is the main cause of dysuria or urinary retention, mainly due to the decrease in bladder contraction (the decrease in contraction amplitude or duration) or the increase in outflow tract resistance. Sacral neuromodulation (SNM) has been used for > 10 years to treat many kinds of lower urinary tract dysfunction. It has become increasingly popular in China in recent years. Consequently, studies focusing on non-neurogenic, non-obstructive dysuria patients treated by SNM are highly desirable.AIM: To assess the outcome of two-stage SNM in non-neurogenic, non-obstructive dysuria.METHODS: Clinical data of 54 patients (26 men, 28 women) with non-neurogenic, non-obstructive dysuria treated by SNM from January 2012 to December 2016 in ten medical centers in China were retrospectively analyzed. All patients received two or more conservative treatments. The voiding diary, urgency score, and quality of life score before operation, after implantation of tined lead in stage I (test period), and during short-term follow-up (latest follow-up) after implantation of the implanted pulse generator in stage II were compared to observe symptom improvements.RESULTS: Among the 54 study patients, eight refused to implant an implanted pulse generator because of the unsatisfactory effect, and 46 chose to embed the implanted pulse generator at the end of stage I. The conversion rate of stage I to stage II was 85.2%. The average follow-up time was 18.6 mo. There were significant differences between baseline (before stage I) and the test period (after stage I) in residual urine, voiding frequency, average voiding amount, maximum voiding amount, nocturia, urgency score, and quality of life score. The residual urine and urgency score between the test period and the latest follow-up time (after stage II) were also significantly different. No significant differences were observed for other parameters. No wound infection, electrode breakage, or other irreversible adverse events occurred.CONCLUSION: SNM is effective for patients with non-neurogenic, non-obstructive dysuria showing a poor response to traditional treatment. The duration of continuous stimulation may be positively correlated with the improvement of residual urine.

medicine, general & internal
Sacral Nerve Stimulation For The Treatment Of Refractory Overactive Bladder: Preliminary Results

Z. Liu,X. Tian,L. Ma

DOI: https://doi.org/10.3969/j.issn.1009-6604.2017.04.009

2017-01-01

Abstract:Objective To evaluate the effectiveness and safety of sacral nerve stimulation (SNS) for the treatment of refractory overactive bladder (OAB).Methods We analyzed clinical data of 9 patients with refractory OAB from May 2016 to October 2016 retrospectively.The 9 patients were treated with SNS, which consisted of experimental therapy and permanent implantation therapy.Antibiotics of third generation quinolones and second generation cephalosporins were used to prevent infection after surgery.The data of voiding diary (including average urinary frequency of 24 h in 5 d and average micturition volume of 24 h in 5 d), overactive bladder symptom score (OABSS), O'Leary-Sant problem and symptom index (OPSI), interstitial cystitis problem index (ICPI) and interstitial cystitis symptom index (ICSI) were collected.All the patients were followed up for adverse reactions related to operation, related to stimulation and related to the device.Results All the 9 cases accepted permanent implantation therapy after a period of experimental therapy with satisfactory curative effects.The success rate of permanent implantation in this group was 100%.The interval time between experimental therapy and permanent implantation therapy was 6-22 days, with an average of (9.6±5.0) days.Postoperative follow-up time ranged from 3-8 months, with an average of (6.1±1.5) months.Before the surgery, the average urinary frequency of 24 h was (34.0±16.7) times.After surgery, the data was (18.0±4.5) times.There was significant difference before and after surgery (t=3.648, P=0.007).The difference was also statistically significant (t=-4.314, P=0.003) between preoperative average micturition volume of 24 h (106.5±44.6 ml) and postoperative micturition volume (140.8±38.3 ml).Before the surgery, the OABSS, OPSI, ICPI and ICSI were (10.8±1.7), (31.6±2.4), (14.4±1.1), and (17.1±1.6) points.After surgery, the data were (6.3±3.3), (16.0±3.5), (6.8±2.5), and (9.2±2.6) points.The scores were significantly improved or the differences were statistically significant in the OABSS (t=5.946, P=0.000), OPSI (t=9.061, P=0.000), ICPI (t=7.667, P=0.000) and ICSI (t=6.475, P=0.000).Surgery related adverse reactions such as infection, bleeding, neurological or vascular injury did not occur.There were no stimulation related adverse reactions such as implantation site pain, new pain and bowel function changes, transient mild electric shock feeling and device related adverse reactions (electrode breakage, short electrode, dysfunction, part corrosion and infection).Conclusion Initial clinical results show that SNS is safe and effective for patients with refractory OAB who are not well treated by conservative treatment.
Preliminary analysis of stimulation parameters for sacral neuromodulation in different indications: A multi-center retrospective cohort study from China

Lingfeng Meng,Zehao Yan,Xinhao Wang,Yaoguang Zhang,Zhikai Zhu,Wen Zhu,Qing Ling,Xiaoke Sun,Yinjun Gu,Jianwei Lv,Yan Li

DOI: https://doi.org/10.1097/js9.0000000000001302

2024-03-04

International Journal of Surgery

Abstract:Background: Sacral neuromodulation (SNM) is an effective approach for treating lower urinary tract dysfunction (LUTD), and stimulation programming is essential for successful treatment. However, research on SNM programming for various indications is limited. Thus, we aimed to determine whether there were differences in the stimulation parameters for different SNM indications and the appropriate programming recommendations. Materials and Methods: Clinical data were retrospectively collected from patients with LUTD who underwent SNM and completed internal pulse generator (IPG) implantation. The parameters with the highest patient satisfaction or the most symptom improvement during the test period were considered optimal and used to set the programming after IPG implantation. Results: After screening, 282 patients were enrolled and categorized into four groups based on the following indications: refractory overactive bladder (OAB) (n=61), neurogenic lower urinary tract dysfunction (nLUTD) (n=162), interstitial cystitis/painful bladder syndrome (IC/BPS) (n=24), and idiopathic non-obstructive urinary retention (NOUR) (n=35). When analyzing the optimal stimulus parameters, disparities in the stimulation amplitude and pulse frequency were noted among the four groups. The stimulation amplitude in the nLUTD group was higher than that in the idiopathic NOUR group ( P =0.013). Differences in pulse frequency were observed between the refractory OAB and nLUTD groups ( P <0.001) and between the refractory OAB and idiopathic NOUR groups ( P =0.001). No differences in the electrode configuration or pulse width settings existed among the four groups. Conclusions: The stimulation parameters for SNM varied among the different indications. For the initial programming of stage I, most patients are recommended to start with stimulation amplitudes below 2 V, although patients with nLUTD may benefit from higher amplitudes. A standard pulse width of 210 μs is recommended for all patients. However, for individuals experiencing nLUTD or idiopathic NOUR, the pulse frequency can begin above the standard 14 Hz but not exceed 50 Hz.

surgery
Shapley Value in a Model of Information Transferal

Patricia Lucia Galdeano,J. Oviedo,L. Quintas

DOI: https://doi.org/10.1142/S0219198910002490

2010-03-01

Abstract:In this paper we analyze the value of the information in a cooperative model. There is an agent (the innovator), having relevant information which can be sold to some potential buyers. The n potential users of the information share a market. The expected utility of each of them can be improved by obtaining the information. The whole situation is modelled as a (n + 1)–person cooperative game.We study the properties of the characteristic function of this game. It fulfills a weak version of the superadditivity property, namely 0-monotonicity. The game is proved to be monotonic.We compute the Shapley value and we prove it is an imputation for the game. We compare the Shapley value with the equilibrium studied in a noncooperative model by Quintas (1995). We also study some limit cases when the potential buyers are completely informed or uninformed. It includes Big Boss Games (Muto et al. (1988)) and other limit cases.We conclude that in a cooperative environment the buyers avoid being exploited by the innovator. Conversely the innovator obtains a higher utility in a noncooperative game.
[Application of sacral nerve stimulation in patients with fecal incontinence].

Yingjiang Ye,Zhanlong Shen,Shan Wang

DOI: https://doi.org/10.3760/cma.j.issn.1671-0274.2014.03.027

2014-01-01

Abstract:Fecal incontinence is one of diseases effecting the quality of life and mental health. Germany surgeon used sacral nerve stimulation(SNS) to treat fecal incontinence at first in 1995. The aim of SNS is to mobilize the ability to control the feces through stimulating the nerves of dominating the sphincter muscles and pelvic floor muscles. Standard SNS includes two stages: evaluation stage of SNS and permanent implantation stage. Preoperative evaluation plays important role in guaranteeing the success of treatment. SNS is the primary treatment of choice for severe fecal incontinence. The complications of SNS include pain, shift of electronic probe, wound dehiscence, bowel dysfunction and infection.
The Application Value of H-reflex Induced by Electrical Stimulation of the Sacral Nerve at the S3 Foramen in Stimulus Parameter Programming

Yu Min,Haofei Jiang,Hao Jin,Yanlan Yu,Guoqing Ding,Haihong Jiang

DOI: https://doi.org/10.1088/1742-6596/2809/1/012005

2024-01-01

Journal of Physics Conference Series

Abstract:Although manufacturers of sacral nerve stimulators and related research have provided many guiding opinions on the programming values of stimulation parameters, the stimulation parameters used for long-term treatment of patients are still largely influenced by the experience of doctors and the subjective feelings of patients. We found a high positive correlation between the appearance and amplitude growth trend of the H-reflex induced by S3 nerve root stimulation, the stimulation amplitude corresponding to the inflection point, and the subjective sensation threshold and pain threshold of patients who underwent the first phase of implantable stimulatory surgery, through electromyography collection. Based on this, we believe that the information on the H-reflex triggered by S3 nerve root stimulation will provide a more intuitive and quantifiable non-invasive way for doctors to assist in determining the appropriate stimulator amplitude for long-term treatment of patients. This will help reduce unnecessary pain and potential permanent nerve damage risks that may occur to patients during parameter programming and debugging processes. Especially when facing patients with communication barriers or lack of cooperation, it is more meaningful.
Preliminary analysis of stimulation parameters for sacral neuromodulation in different indications: a multicenter retrospective cohort study from China

Lingfeng Meng,Zehao Yan,Xinhao Wang,Yaoguang Zhang,Zhikai Zhu,Wen Zhu,Qing Ling,Xiaoke Sun,Yinjun Gu,Jianwei Lv,Yan Li

DOI: https://doi.org/10.1097/JS9.0000000000001302

2024-06-01

Abstract:Background: Sacral neuromodulation (SNM) is an effective approach for treating lower urinary tract dysfunction (LUTD), and stimulation programming is essential for successful treatment. However, research on SNM programming for various indications is limited. Thus, the authors aimed to determine whether there were differences in the stimulation parameters for different SNM indications and the appropriate programming recommendations. Materials and methods: Clinical data were retrospectively collected from patients with LUTD who underwent SNM and completed internal pulse generator implantation. The parameters with the highest patient satisfaction or the most symptom improvement during the test period were considered optimal and used to set the programming after internal pulse generator implantation. Results: After screening, 282 patients were enrolled and categorized into four groups based on the following indications: refractory overactive bladder (OAB) ( n =61), neurogenic lower urinary tract dysfunction (nLUTD) ( n =162), interstitial cystitis/painful bladder syndrome (IC/BPS) ( n =24), and idiopathic nonobstructive urinary retention (NOUR) ( n =35). When analyzing the optimal stimulus parameters, disparities in the stimulation amplitude and pulse frequency were noted among the four groups. The stimulation amplitude in the nLUTD group was higher than that in the idiopathic NOUR group ( P =0.013). Differences in pulse frequency were observed between the refractory OAB and nLUTD groups ( P <0.001) and between the refractory OAB and idiopathic NOUR groups ( P =0.001). No differences in the electrode configuration or pulse width settings existed among the four groups. Conclusions: The stimulation parameters for SNM varied among the different indications. For the initial programming of stage I, most patients are recommended to start with stimulation amplitudes below 2 V, although patients with nLUTD may benefit from higher amplitudes. A standard pulse width of 210 μs is recommended for all patients. However, for individuals experiencing nLUTD or idiopathic NOUR, the pulse frequency can begin above the standard 14 Hz but not exceed 50 Hz.
Treatment of the infected sacral nerve stimulator: A scoping review

Jessica Wynn,Ellen Kelsey,Kathryn McLeod

DOI: https://doi.org/10.1002/nau.25411

IF: 2.367

2024-02-08

Neurourology and Urodynamics

Abstract:Background Sacral nerve stimulators (SNSs) are a widely accepted, efficacious surgical option to treat patients who have failed conservative management for overactive bladder, nonobstructive urinary retention, fecal incontinence, or pelvic pain. As with all implanted devices, there are associated risks for surgical site and implant infections. There are currently no clear published data or guidelines regarding treating such infections. Aims We present a scoping review aiming to examine the existing literature on the treatment approaches of infected SNSs. Methods A scoping review was conducted using Preferred Reporting Items for Systematic Review and Meta‐Analysis. The search strategy focused on "sacral modulation," and "infection," and "explantation," and conservative management methods such as "antibiotics." A search was conducted on medical databases, and a grey literature search was performed. Results Thirty articles were included for data extraction. Articles were published between 2006 and 2022. Outcomes were reported for 7446 patients. Two hundred and seventy‐four infection events were reported, giving an overall 3.7% infection rate. Most infection events were treated with explantation, although there is some discussion on the role of conservative management using oral and intravenous antibiotics in the literature. Articles also discussed considerations for future reimplantation after explantation of SNS. Conclusions There are currently no treatment protocols in the literature to help guide whether a patient is suited to conservative or surgical management. There is future scope for developing treatment algorithms to guide clinicians for optimal treatment of infected sacral neuromodulation devices.

urology & nephrology
Feasibility of Sacral Neuromodulation in Patients with Underlying Neurologic Lower Urinary Tract Dysfunction and Fecal Incontinence

Schwarztuch Gildor Omri,Neheman Amos,Vainrib Michael

DOI: https://doi.org/10.1016/j.urology.2024.02.034

IF: 2.633

2024-02-29

Urology

Abstract:Purpose To evaluate the efficacy and safety of sacral neuromodulation (SNM) in patients with underlying neurologic conditions and compare outcomes to non-neurogenic patients. Methods Between 2017-2022 patients undergoing 2-staged implantation of InterStimTM II were included in a single-center retrospective study. Patients were allocated into two groups: underlying neurologic conditions (Group1) or non-neurogenic (Group2). Efficacy and safety were evaluated by comparing patients' bladder/bowel logs pre- and post-operative. Patients' demographics, indications, pre-implantation urodynamic study (UDS) variables, surgery duration, number of post-op visits, and time to revision/removal procedures were compared and included in the data analysis. Results 67 patients (64.2% female) with a mean age of 63.23±14.15 years were included in the study – 16/67(23.9%) patients assigned to Group 1. There is no statistically significant difference between the groups regarding the indication for the treatment. The most common indication was non-obstructing urinary retention (NOUR) in both study groups. The common neurologic pathologies were multiple sclerosis, disc disease, and spinal stenosis. Overall and sub-group (based on an indication for SNM implantation) analyses showed no significant difference in patients' demographics, the surgery duration, or the chances for clinical success with a similar follow-up period. During the follow-up, the device was removed in 4 (25.0%) and 10 (19.6%) of the patients in Group 1 and Group 2, respectively (p=0.912). There was no significant difference between the groups in the time till InterStimTM II removal (p=0.905). All NOUR patients with clinical success in Group 1 had an improvement of at least 75% from the baseline compared to 69% of patients in Group 2 (p=0.42). Univariate analysis in NOUR patients demonstrated that maximal cystometric capacity below 430 mL and the presence of detrusor contraction at voiding were statistically significant predictors of successful SNM. Overall, at the end of the follow-up period, 8 (50.0%) and 29 (56.9%) patients in Groups 1 and 2, respectively, were defined as clinical success (p=0.775).

urology & nephrology
Clinical Effect of Repetitive Functional Magnetic Stimulation of Sacral Nerve Roots on Urinary Retention after Spinal Cord Injury: a Case-Control Study

Yan Li,Bing-Chen An,Jing-Jing Zhang,Yan Chen,Ling-Li Wu,Fang Gao

DOI: https://doi.org/10.4103/2773-2398.340142

2022-01-01

Brain Network and Modulation

Abstract:Urinary retention is a serious complication of spinal cord injury. This study examined whether repetitive functional magnetic stimulation (rFMS) applied over the sacral nerve root affected bladder function or mood in patients with urinary retention after spinal cord injury. This single-center, case-control study included 32 patients with detrusor flaccid neurogenic bladder after spinal cord injury, who were randomly assigned to rFMS (n = 11), electroacupuncture pudinal nerve stimulation (EAPNS; n = 11), and control groups (n = 10). All groups received routine bladder function training. The S3 sacral nerve was stimulated at a frequency of 5 Hz, once per day for 4 consecutive weeks in the rFMS group. Electroacupuncture stimulation of the pudendal nerve was performed once daily for 4 weeks in the EAPNS group. The control group received bladder function retraining alone. After the 4-week treatment, there were significant improvements in all three groups (P < 0.05). Primary bladder sensation, maximum bladder volume, maximum bladder pressure, and residual urine were significantly higher in the rFMS group than in the other two groups (P < 0.05). Primary bladder sensation, maximum bladder volume, residual urine, and urinary leukocyte count were significantly different between the EAPNS and control groups (P < 0.05). The rFMS group had significantly lower scores in the self-rated anxiety scale and self-rated depression scale compared with those of the other two groups. The quality of life score significantly increased in all three groups. rFMS is conducive to the recovery of neurogenic function in patients with urinary retention. This study provides a scientific basis for the clinical application and promotion of rFMS.
Sacral neuromodulation for Organophosphate-induced delayed neuropathy neurogenic lower urinary tract dysfunction: a case report

Junjie Han,Dingliang Zhao,Shuqiang Feng,Xuesong Yang,Yinchun Wang,Zhenhua Dong,Zhao Sun,Ziyuan Deng,Yi Zhang,Ranwei Li

DOI: https://doi.org/10.1186/s12894-024-01600-x

2024-10-05

BMC Urology

Abstract:Organophosphate-Induced Delayed Neuropathy (OPIDN) is a rare neurological disorder triggered by exposure to organophosphorus compounds. These compounds exert their neurotoxic effects by impacting the nervous system, leading to systemic manifestations. Urinary system symptoms are infrequently observed in clinical settings. Currently, effective therapeutic interventions for OPIDN-related urinary symptoms are lacking. Sacral nerve modulation therapy, an FDA-approved approach for managing lower urinary tract symptoms, presents as a promising option. Herein, we present a case of OPIDN-induced lower urinary tract obstruction successfully treated with sacral nerve modulation therapy, resulting in substantial symptom relief.

urology & nephrology
Genomic organization of a mouse glyceraldehyde 3-phosphate dehydrogenase gene (Gapd-s) expressed in post-meiotic spermatogenic cells.

J. E. Welch,P. Brown,Deborah A. O'Brien,Deborah A. O'Brien,Edward M. Eddy

DOI: https://doi.org/10.1002/DVG.1020160210

Developmental Genetics

Abstract:The Gapd-s gene encodes an isoform of the glyceraldehyde 3-phosphate dehydrogenase enzyme expressed only in post-meiotic spermatogenic cells. Two clones containing the Gapd-s gene were isolated from a mouse genomic library. Sequencing and restriction enzyme analysis demonstrated that this single-copy gene contains 11 exons and spans 9596 base pairs. The locations of Gapd-s exons and introns are conserved when compared to the corresponding portions of the chicken and human somatic Gapd genes. The promoter region contains no TATA box, although there is a potential SP1 recognition site within exon 1. Like other TATA-less genes, primer extension analysis reveals some heterogeneity in the site of transcription initiation with Gapd-s transcripts initiating from three discrete sites. Northern analysis demonstrated that a 1.5-kb Gapd-s mRNA is expressed in the testis in at least three mammalian orders, indicating that the Gapd-s gene appeared early in mammalian evolution. Using GAPD-deficient bacteria, mouse GAPD-S was shown to be capable of functioning as a glycolytic enzyme. Since GAPD has been proposed to be a key enzyme regulating glycolysis in spermatogenic cells, GAPD-S may represent a potential target for toxicological or contraceptive agents affecting fertility by interfering with glycolysis.
Stanniocalcin-1 is induced by hypoxia inducible factor in rat alveolar epithelial cells.

Yoko Ito,R. Zemans,K. Correll,Ivana V. Yang,Aftab Ahmad,B. Gao,R. Mason

DOI: https://doi.org/10.1016/j.bbrc.2014.09.060

2014-10-03

Abstract:
Outcomes of sacral neuromodulation in male patients with overactive bladder, chronic pelvic pain, and fecal incontinence

Roseanne Ferreira,Emad Alwashmi,Samuel Otis-Chapados,Naeem Bhojani,Kevin C Zorn,Bilal Chughtai,Dean S Elterman

Abstract:Introduction: Despite the growing body of literature on sacral neuromodulation (SNM) outcomes, research focusing on male patients remains limited and often represented by small cohorts nested within a larger study of mostly women. Herein, we evaluated the outcomes of SNM in a male-only cohort with overactive bladder (OAB), fecal incontinence (FI), chronic bladder pain, and neurogenic lower urinary tract dysfunction (NLUTD). Materials and methods: This retrospective cohort study included 64 male patients who underwent SNM insertion between 2013 and 2021 at a high-volume tertiary center. Indications for SNM therapy included OAB, FI, chronic pelvic pain, and NLUTD. Descriptive statistics, Fisher's and t-test were used in analysis. Results: The mean age was 57.7 ± 13.4 years, and the most frequent reason for SNM insertion was idiopathic OAB (72%), FI (16%), pelvic pain (11%), and NLUTD (11%). A majority (84%) of men received treatment prior to SNM insertion. 84% reported satisfaction and 92% symptom improvement within the first year, and these improvements persisted beyond 1 year in 73% of patients. Mean follow up was 52.7 ± 21.0 months. The complication rate was 23%, and the need for adjunct treatments was significantly reduced (73% to 27%, p < 0.001). Treatment outcomes did not differ significantly between various indications for SNM therapy or the presence of benign prostatic hyperplasia (BPH). Conclusion: SNM is an effective and safe procedure for male patients with neurogenic and non-neurogenic OAB, pelvic pain, and FI. Over 70% of patients experienced symptomatic improvement and remained satisfied in the mid to long term follow up. BPH does not seem to hinder treatment outcomes.
Early Sacral Neuromodulation Prevented Detrusor Overactivity in Rats With Spinal Cord Injury

Linchen Lv,Wenxian Li,Dongyue Guo,Benkang Shi,Yan Li

DOI: https://doi.org/10.1016/j.neurom.2024.05.008

2024-07-23

Neuromodulation

Abstract:Objectives: Sacral neuromodulation (SNM) has been shown to alleviate bladder dysfunction in patients with overactive bladder and nonobstructive urinary retention. However, the therapeutic effect and mechanism of SNM in neurogenic bladder dysfunction are still not fully understood. Using a rat model of spinal cord injury (SCI), this study aims to investigate the therapeutic effect of early SNM in the bladder-areflexia phase on neurogenic bladder dysfunction and evaluate its possible mechanism. Materials and methods: Basic physiological parameters such as body/bladder weight, blood pressure, and electrocardiogram results were measured to evaluate the safety of SNM. Enzyme-linked immunosorbent assays and quantitative real-time polymerase chain reaction were used to examine the expression of proinflammatory factors. Hematoxylin and eosin and Masson's trichrome staining were used to observe morphological changes, and cystometry was used to evaluate urodynamic changes after SNM treatment. Western blotting and immunofluorescence staining were used to measure the levels of transient receptor potential vanilloid 1 (TRPV1) and calcitonin gene-related peptide (CGRP) in the L6-S1 dorsal root ganglia (DRGs) and bladder. Capsaicin desensitization was used to investigate whether inhibiting TRPV1 could prevent detrusor overactivity in SCI rats. Results: Early SNM did not affect the body/bladder weight, heart rate, blood pressure, or the expression of proinflammatory cytokines (PGE2, IL-1, IL-2, IL-6, TGF-β, or TNF-α) in the bladders of SCI rats. Morphologically, early SNM prevented urothelial edema (p = 0.0248) but did not influence collagen/smooth muscle in the bladder. Compared with untreated rats with SCI, the rats treated with SNM exhibited increased bladder capacity (p = 0.0132) and voiding efficiency (p = 0.0179), and decreased nonvoiding contraction (NVC) frequency (p = 0.0240). The maximum pressure, basal pressure, postvoid residual, and NVC amplitude did not change significantly. After the SNM treatment, the expression of TRPV1 in the bladder and CGRP in L6-S1 DRGs weredecreased (L6, p = 0.0160; S1, p = 0.0024) in SCI rats. In capsaicin-desensitized SCI rats, urodynamic results showed an increase in bladder capacity (p = 0.0116) and voiding efficiency (p = 0.0048), and diminished NVC frequency (p = 0.0116), while other parameters did not change significantly. Conclusions: Early SNM prevented urothelial edema morphologically and detrusor overactivity in SCI rats. Inhibition of TRPV1 in the bladder and DRGs may be one of the potential mechanisms for preventing detrusor overactivity by SNM.
Risk factors for complications following sacral neuromodulation for faecal incontinence: Long‐term follow‐up

Rachel Gefen,Victor Strassmann,Felice De Stefano Hernandez,Zoe Garoufalia,Nir Horesh,Sameh Hany Emile,Giovanna Da Silva,Steven Wexner

DOI: https://doi.org/10.1111/codi.17092

IF: 3.4

2024-07-14

Colorectal Disease

Abstract:Aim Sacral neuromodulation (SNM) has become a standard surgical treatment for faecal incontinence (FI). Prior studies have reported various adverse events of SNM, including suboptimal therapeutic response, infection, pain, haematoma, and potential need for redo SNM. The aim of this study was to identify the risk factors associated with long‐term complications of SNM. Method This retrospective cohort reviewed patients who underwent two‐stage SNM for FI at our institution between 2011–2021. Preoperative baseline characteristics and follow‐up were obtained from the medical record and/or by telephone interview. Management and outcome of each postoperative event were evaluated by univariate and multivariate regression analyses. Results A total of 291 patients (85.2% female) were included in this study. Postoperative complications were recorded in 219 (75.2%) patients and 154 (52.9%) patients required surgical intervention to treat complications. The most common postoperative event was loss of efficacy (46.4%). Other common adverse events were problems at the implant site (pain, infection, etc.) in 16.5% and pain during stimulation in 11.7%. Previous vaginal delivery (OR 2.74, p = 0.003) and anal surgery (OR = 2.46, p = 0.039) were independent predictors for complications. Previous colorectal (OR = 2.04, p = 0.026) and anal (OR = 1.98, p = 0.022) surgery and history of irritable bowel syndrome (IBS) (OR = 3.49, p = 0.003) were independent predictors for loss of efficacy. Conclusion Postoperative adverse events are frequently recorded after SNM. Loss of efficacy is the most common. Previous colorectal or anal surgery, vaginal delivery, and IBS are independent risk factors for complications.

gastroenterology & hepatology,surgery
Permanent sacral nerve modulation for fecal incontinence and associated urinary disturbances

Donato F Altomare,Marcella Rinaldi,Maria Petrolino,Vincenzo Monitillo,Pierluca Sallustio,Antonella Veglia,Michele De Fazio,Altomarino Guglielmi,Vincenzo Memeo

DOI: https://doi.org/10.1007/s00384-003-0523-y

Abstract:Background and aims: Sacral nerve modulation (SNM) using an implantable pulse generator is gaining increasing acceptance in the treatment of several functional disturbances of the urinary and intestinal tract. This new therapeutic approach offers new possibilities in the treatment of fecal incontinence (FI) by means of its possible effects on anorectal physiology. Patients and methods: Fourteen patients with FI, six of whom had associated urinary disturbances, underwent permanent SNM after successful peripheral nerve evaluation tests. All had a clinical evaluation including FI grading systems (American Medical systems, AMS; Continence Grading System, CGS) and quality of life questionnaires (Fecal Incontinence Quality of Life, FIQL), and anorectal physiology tests performed before and during electrostimulation. Two patients had a lead displacement which was repositioned. Median follow-up was 14 months (range 6-48 months). Results: AMS scores decreased significantly from 101 to 67 after 24 months CGS scores from 15 to 2 after 2 months. The median number of episodes of major incontinence per 2 weeks decreased from 14 to 1 after 24 months. FIQL scores improved significantly in the nine patients tested from an overall score of 1.59 to 3.3, with improvement in all areas of the FIQL. Four of the six patients with associated urinary disturbances had a significant improvement in their symptoms. Anal resting and squeezing tone did not change significantly, nor did rectal volumetry, compliance, rectoanal inhibitory reflex, or length of the anal high-pressure zone, while 24-h rectal manometry showed inhibition of the spontaneous rectal motility complexes after meal and on awakening in the only two patients undergoing this investigation. Conclusion: Although the mechanism of action of SMN is still unclear and requires further investigations, clinical results are very encouraging, confirming the role of this new and safe procedure in the treatment of FI and associated urinary disturbances.
Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device

Yaoguang Zhang,Peng Zhang,Xiaojun Tian,Guoqing Chen,Yan Li,Yong Zhang,Zhihui Xu,Zhongqing Wei,Wei Zhang,Lulin Ma,Benkang Shi,Limin Liao,Jianye Wang

DOI: https://doi.org/10.1007/s00345-019-02698-7

2019-01-01

World Journal of Urology

Abstract:Purpose The efficacy and safety of a novel remotely programmed BetterStim sacral neuromodulation (SNM) system was evaluated in patients with refractory overactive bladder (OAB) in a prospective, controlled, multicenter trial. Methods A total of 84 patients referred for SNM therapy from October 2015 to January 2018 were studied. Of the patients who qualified for implantation, 37 and 33 were randomly assigned to treatment and control groups, respectively. Patients in the treatment group underwent stimulation upon implantation, while stimulation was delayed in the control group for 3 months. Follow-up visits, consisting of voiding diary outcome, questionnaires regarding overactive bladder symptom score (OABSS) and quality of life were conducted at 1, 3, and 6-month post-implantation. Results Compared with the control group, subjects in the treatment group exhibited statistically significant improvement in OAB symptoms at 3 months. The overall success rate was achieved in 72% of the treatment group, compared with 12% of the control group at 3 months. At 6 months, there were no significant differences in key voiding diary variables between the two groups. Further, this study demonstrated sustained improvement in urinary symptom interference in OAB patients. In addition, nearly all patients expressed great satisfaction with the remote-programming methods. No serious adverse events occurred, and device-related adverse events rate was 12.86%. Conclusion This clinical study demonstrates subjective and objective success of the BetterStim SNM system. Importantly, our data suggest that remote programming can be safely used as a viable option for the conventional programming with a high degree of patient satisfaction.
AB291. SPR-18 Correlation of sacral nerve lead targeting and urological efficacy: motor mapping, electrode position, and stimulation amplitude

Lance Zirpel,Xin Su,Janine Wotton,Nicki Reinking,Adam Steiner,Dwight E. Nelson,Thaddeus S. Brink

DOI: https://doi.org/10.21037/tau.2016.s291

2016-12-01

Translational Andrology and Urology

Abstract:Sacral neuromodulation (SNM) is a clinically used therapy for refractory urge frequency and incontinent patients. Using a recently developed sheep model, this preclinical study retrospectively evaluated the relationship between implanted sacral lead locations, motor threshold (MT) values, motor mapping, and acute urological efficacy to determine if acute location and physiological measurements are correlated. Twelve female polypay sheep were implanted with bilateral InterStim® devices (Model 3058) connected to quadripolar leads (model 3889) placed in the S2-4 foramina with S3 as the ideal target. CT scans at post-op and ≥12 months later were used for 3D rendering using MedCAD points placed on the sacrum and lead contacts to compare coordinates across animals. Acute cystometry was performed to test responses to SNM (0.21 ms PW, 10 Hz) at maximum tolerable amplitude (MTA). MT values were obtained by visual identification of the first motor response and the motor reflex was mapped to an anatomical map. Sheep were categorized as responders (n=6; 50%) or non-responders (n=6; 50%) based on ≥50% increase in bladder capacity to acute SNM. There was a significant difference in motor mapping areas between responders (peri-anal contacts) and non-responders (activation of leg) (chi-square; P<0.05). Higher MTA values correlated with larger bladder capacity increases (Pearson correlation; P<0.05). Contact position correlated with urological response (ANOVA; P<0.05). A generalized Procrustes analysis on the 17 leads in S3 (remainder in S2 or S4) showed variability of distributions was higher in distal contacts (0 & 1, mean distance to center 7.3±1.8 mm, left & 6.8±1.3 mm, right) than proximal (2 & 3, mean distance to center 5.8±0.86 mm, left & 4.3±0.35 mm, right (ANOVA; alpha =0.05; F(3,64) =20.55; P<0.0001). (I) Responder sheep showed motor responses in peri-anal areas significantly more often than non-responders; (II) MTA weakly correlated with increased bladder capacity; (III) activation of lead contacts proximal to the sacral foramen produced more reliable urological results than did activation of distal contacts. These results suggest well-positioned leads will elicit specific responses that could be essential to effective SNM therapy. Future work will characterize changes over time to provide a temporal correlation of this relationship. Medtronic

urology & nephrology,andrology
Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study

A C van Voskuilen,D J A J Oerlemans,E H J Weil,R A de Bie,Ph E V A van Kerrebroeck

DOI: https://doi.org/10.1016/j.eururo.2005.11.009

Abstract:Objective: To analyse the influence of technical improvements of Sacral Nerve Stimulation (SNS) on the incidence of surgical interventions and subjective long-term results of SNS. Methods: Retrospective, transversal study analyzing records of implanted patients at our department of Urology. Results: Of 149 patients analyzed, 107 had overactive bladder symptoms and 42 had urinary retention. Mean follow-up was 64,2 (sd = 38,5) months. In the whole group 194 adverse events occurred. 6 Patients had infection in their implanted system, one was explanted for infection. Most events could be solved by giving advice or by reprogramming the stimulator. 129 reoperations have been performed and 21 patients had their system explanted. Analysis of the data shows a striking difference in the incidence of reoperations, but small differences in subjective results in the groups of patients implanted before or after 1996, suggesting that a proactive approach towards adverse events is worthwhile. Conclusions: SNS gives lasting benefit in patients with refractory symptoms of overactive bladder and non-obstructive urinary retention. The differences in outcomes and incidence of reoperation can be attributed to the learning curve and technical and surgical improvements in the application of SNS.

Inhibition of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin.

Clinical outcomes of sacral neuromodulation in non-neurogenic, non-obstructive dysuria: A 5-year retrospective, multicentre study in China

Sacral Nerve Stimulation For The Treatment Of Refractory Overactive Bladder: Preliminary Results

Preliminary analysis of stimulation parameters for sacral neuromodulation in different indications: A multi-center retrospective cohort study from China

Shapley Value in a Model of Information Transferal

[Application of sacral nerve stimulation in patients with fecal incontinence].

The Application Value of H-reflex Induced by Electrical Stimulation of the Sacral Nerve at the S3 Foramen in Stimulus Parameter Programming

Preliminary analysis of stimulation parameters for sacral neuromodulation in different indications: a multicenter retrospective cohort study from China

Treatment of the infected sacral nerve stimulator: A scoping review

Feasibility of Sacral Neuromodulation in Patients with Underlying Neurologic Lower Urinary Tract Dysfunction and Fecal Incontinence

Clinical Effect of Repetitive Functional Magnetic Stimulation of Sacral Nerve Roots on Urinary Retention after Spinal Cord Injury: a Case-Control Study

Sacral neuromodulation for Organophosphate-induced delayed neuropathy neurogenic lower urinary tract dysfunction: a case report

Genomic organization of a mouse glyceraldehyde 3-phosphate dehydrogenase gene (Gapd-s) expressed in post-meiotic spermatogenic cells.

Stanniocalcin-1 is induced by hypoxia inducible factor in rat alveolar epithelial cells.

Outcomes of sacral neuromodulation in male patients with overactive bladder, chronic pelvic pain, and fecal incontinence

Early Sacral Neuromodulation Prevented Detrusor Overactivity in Rats With Spinal Cord Injury

Risk factors for complications following sacral neuromodulation for faecal incontinence: Long‐term follow‐up

Permanent sacral nerve modulation for fecal incontinence and associated urinary disturbances

Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device

AB291. SPR-18 Correlation of sacral nerve lead targeting and urological efficacy: motor mapping, electrode position, and stimulation amplitude

Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study